Telomir director resets 25K stock options at $1.30

Telomir Pharmaceuticals director Whalen Matthew Pratt reported an option restructuring.

Accepted by SEC EDGAR 05/22/2026 - 08:00 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Telomir Pharmaceuticals director Whalen Matthew Pratt reported an option restructuring. He agreed to cancel 25,000 incentive stock options with a $5.02 exercise price in exchange for 25,000 new options with a lower $1.30 exercise price, expiring on May 21, 2036. Following these transactions, he holds 25,000 incentive stock options that are fully exercisable.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Whalen Matthew Pratt

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Options (right to buy)	25,000	$0.00	$0.00
Disposition	Incentive Stock Options (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Incentive Stock Options (right to buy) — 25,000 contracts (Direct)

Footnotes (2)

F1. The options are fully exercisable.
F2. The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price.

Key Figures

Cancelled options: 25,000 options New option grant: 25,000 options Old exercise price: $5.02/share +3 more

6 metrics

Cancelled options 25,000 options Disposition to issuer at $5.02 exercise price

New option grant 25,000 options Grant at $1.30 exercise price

Old exercise price $5.02/share Cancelled incentive stock options

New exercise price $1.30/share New incentive stock options

New option expiry May 21, 2036 Expiration date of new grant

Post-transaction options 25,000 options Total incentive stock options held after transactions

Key Terms

Incentive Stock Options (right to buy), Disposition to issuer, Grant, award, or other acquisition, exercise price, +1 more

5 terms

Incentive Stock Options (right to buy) financial

"security_title: Incentive Stock Options (right to buy)"

Disposition to issuer financial

"transaction_code_description: Disposition to issuer"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 5.0200 and 1.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully exercisable financial

"footnote: The options are fully exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Telomir Pharmaceuticals (TELO) report for Whalen Matthew Pratt?

Telomir Pharmaceuticals reported that director Whalen Matthew Pratt canceled 25,000 incentive stock options with a $5.02 exercise price and received 25,000 new options with a $1.30 exercise price, leaving his total incentive stock option holdings at 25,000.

Did the Telomir (TELO) director increase or decrease his total option holdings?

The director’s total option holdings remained the same at 25,000 shares. He exchanged an existing option grant for a new one with a lower exercise price, so the share count stayed constant while the terms of the options changed.

What are the key terms of the new stock options granted to the Telomir (TELO) director?

The new grant covers 25,000 incentive stock options on Telomir common stock with an exercise price of $1.30 per share. These options are fully exercisable and are scheduled to expire on May 21, 2036, according to the reported Form 4 data.

What happened to the prior stock option grant for the Telomir (TELO) director?

The prior option grant for 25,000 shares with a $5.02 exercise price was canceled and returned to the issuer. This disposition to the issuer was agreed in exchange for receiving a new option grant with more favorable exercise terms for the same number of shares.

How does this Form 4 filing affect Telomir (TELO) common stock directly?

The Form 4 reflects changes to a director’s incentive stock option awards, not direct trades in common shares on the open market. It shows a cancellation and a new option grant, so it primarily affects his compensation structure rather than immediate share float.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whalen Matthew Pratt

(Last)

(First)

(Middle)

C/O TELOMIR PHARMACEUTICALS, INC.

900 WEST PLATT STREET, SUITE 200

(Street)

MIAMI

FLORIDA

33606

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Telomir Pharmaceuticals, Inc. [ TELO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Incentive Stock Options (right to buy)	$1.3	05/21/2026		A		25,000		⁽¹⁾	05/21/2036	Common Stock	25,000	⁽²⁾	25,000⁽²⁾	D
Incentive Stock Options (right to buy)	$5.02	05/21/2026		D			25,000	08/27/2024	08/27/2034	Common Stock	25,000	⁽²⁾	0	D

Explanation of Responses:

1. The options are fully exercisable.

2. The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price.

	/s/ Matthew Pratt Whalen	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR